Cargando…

Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy

Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancr...

Descripción completa

Detalles Bibliográficos
Autores principales: Erstad, Derek J., Sojoodi, Mozhdeh, Taylor, Martin S., Ghoshal, Sarani, Razavi, Allen A., Graham-O'Regan, Katherine A., Bardeesy, Nabeel, Ferrone, Cristina R., Lanuti, Michael, Caravan, Peter, Tanabe, Kenneth K., Fuchs, Bryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078400/
https://www.ncbi.nlm.nih.gov/pubmed/29903803
http://dx.doi.org/10.1242/dmm.034793
_version_ 1783345085937614848
author Erstad, Derek J.
Sojoodi, Mozhdeh
Taylor, Martin S.
Ghoshal, Sarani
Razavi, Allen A.
Graham-O'Regan, Katherine A.
Bardeesy, Nabeel
Ferrone, Cristina R.
Lanuti, Michael
Caravan, Peter
Tanabe, Kenneth K.
Fuchs, Bryan C.
author_facet Erstad, Derek J.
Sojoodi, Mozhdeh
Taylor, Martin S.
Ghoshal, Sarani
Razavi, Allen A.
Graham-O'Regan, Katherine A.
Bardeesy, Nabeel
Ferrone, Cristina R.
Lanuti, Michael
Caravan, Peter
Tanabe, Kenneth K.
Fuchs, Bryan C.
author_sort Erstad, Derek J.
collection PubMed
description Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancreatic ductal adenocarcinoma (PDAC) tumor implantation and characterize phenotypes based on implantation site. Mice (n=8 per group) were implanted with 10(4) cells in the pancreas or flank. Hy15549 and Han4.13 cell lines were derived from primary murine PDAC (Ptf1-Cre; LSL-KRAS-G12D; Trp53 Lox/+) on C57BL/6 and FVB strains, respectively. Single-cell suspension and solid tumor implants were compared. Tumors were treated with two intravenous doses of FOLFIRINOX and responses evaluated. All mice developed pancreatic tumors within 7 days. Orthotopic tumors grew faster and larger than heterotopic tumors. By 3 weeks, orthotopic mice began losing weight, and showed declines in body condition requiring euthanasia starting at 4 weeks. Single-cell injection into the pancreas had near 100% engraftment, but solid tumor implant engraftment was ∼50% and was associated with growth restriction. Orthotopic tumors were significantly more responsive to intravenous FOLFIRINOX compared with heterotopic tumors, with greater reductions in size and increased apoptosis. Heterotopic tumors were more desmoplastic and hypovascular. However, drug uptake into tumor tissue was equivalent regardless of tumor location or degree of fibrosis, indicating that microenvironment differences between heterotopic and orthotopic tumors influenced response to therapy. Our results show that orthotopic and heterotopic allograft locations confer unique microenvironments that influence growth kinetics, desmoplastic response and angiogenesis. Tumor location influences chemosensitivity to FOLFIRINOX and should inform future preclinical trials. This article has an associated First Person interview with the first author of the paper.
format Online
Article
Text
id pubmed-6078400
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-60784002018-08-07 Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy Erstad, Derek J. Sojoodi, Mozhdeh Taylor, Martin S. Ghoshal, Sarani Razavi, Allen A. Graham-O'Regan, Katherine A. Bardeesy, Nabeel Ferrone, Cristina R. Lanuti, Michael Caravan, Peter Tanabe, Kenneth K. Fuchs, Bryan C. Dis Model Mech Research Article Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancreatic ductal adenocarcinoma (PDAC) tumor implantation and characterize phenotypes based on implantation site. Mice (n=8 per group) were implanted with 10(4) cells in the pancreas or flank. Hy15549 and Han4.13 cell lines were derived from primary murine PDAC (Ptf1-Cre; LSL-KRAS-G12D; Trp53 Lox/+) on C57BL/6 and FVB strains, respectively. Single-cell suspension and solid tumor implants were compared. Tumors were treated with two intravenous doses of FOLFIRINOX and responses evaluated. All mice developed pancreatic tumors within 7 days. Orthotopic tumors grew faster and larger than heterotopic tumors. By 3 weeks, orthotopic mice began losing weight, and showed declines in body condition requiring euthanasia starting at 4 weeks. Single-cell injection into the pancreas had near 100% engraftment, but solid tumor implant engraftment was ∼50% and was associated with growth restriction. Orthotopic tumors were significantly more responsive to intravenous FOLFIRINOX compared with heterotopic tumors, with greater reductions in size and increased apoptosis. Heterotopic tumors were more desmoplastic and hypovascular. However, drug uptake into tumor tissue was equivalent regardless of tumor location or degree of fibrosis, indicating that microenvironment differences between heterotopic and orthotopic tumors influenced response to therapy. Our results show that orthotopic and heterotopic allograft locations confer unique microenvironments that influence growth kinetics, desmoplastic response and angiogenesis. Tumor location influences chemosensitivity to FOLFIRINOX and should inform future preclinical trials. This article has an associated First Person interview with the first author of the paper. The Company of Biologists Ltd 2018-07-01 2018-07-30 /pmc/articles/PMC6078400/ /pubmed/29903803 http://dx.doi.org/10.1242/dmm.034793 Text en © 2018. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Research Article
Erstad, Derek J.
Sojoodi, Mozhdeh
Taylor, Martin S.
Ghoshal, Sarani
Razavi, Allen A.
Graham-O'Regan, Katherine A.
Bardeesy, Nabeel
Ferrone, Cristina R.
Lanuti, Michael
Caravan, Peter
Tanabe, Kenneth K.
Fuchs, Bryan C.
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title_full Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title_fullStr Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title_full_unstemmed Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title_short Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
title_sort orthotopic and heterotopic murine models of pancreatic cancer and their different responses to folfirinox chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078400/
https://www.ncbi.nlm.nih.gov/pubmed/29903803
http://dx.doi.org/10.1242/dmm.034793
work_keys_str_mv AT erstadderekj orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT sojoodimozhdeh orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT taylormartins orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT ghoshalsarani orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT razaviallena orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT grahamoregankatherinea orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT bardeesynabeel orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT ferronecristinar orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT lanutimichael orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT caravanpeter orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT tanabekennethk orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy
AT fuchsbryanc orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy